Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adenocarcinoma
Research results from Princess Margaret Hospital update understanding of adenocarcinoma
March 2nd, 2008
In this recently published article, scientists in Toronto, Canada conducted a study "To understand the impact of protein kinase B (PKB; Akt) signaling on growth and protection from apoptosis in pancreatic ductal adenocarcinoma models demonstrating differences in PKB activity. Gemcitabine sensitivity was investigated in a panel of cell lines, characterized by differences in levels of activated PKB." "Suppression of PKB activity was achieved with an inhibitor of phosphatidylinositol 3-kinase (wortmannin) and silencing RNA. Enhanced gemcitabine (2',2'-difluoro-2'-deoxycytidine)-induced cytotoxicity in vitro was achieved with suppression of high PKB activity with...
Source: Pharma Investments, Ventures & Law Weekly (2008-03-02)
|
